메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Newton™ (Formerly Neurolens®) Partners with Hong Kong Optical Lens to Bring Therapeutic and Preventive Vision Solutions to Hong Kong and China Markets

DALLAS, Nov. 19, 2025 -- Newton™, Inc. (formerly Neurolens®), a leader in innovative eye care technology, today announced its expansion into Asian markets through a strategic partnership with Hong Kong Optical Lens Co Ltd (HKO) as the exclusive distributor for Hong Kong and China. This milestone in Newton's international growth brings the therapeutic solution of Neurolens for headaches, neck pain, and motion sickness, along with the everyday digital eye strain prevention of Sequel™ lenses, to millions across two of the world's most digitally connected markets. This
- 김갑성 기자
- 2025-11-19 19:00
Waterdrop Inc. to Report Third Quarter 2025 Financial Results on December 3, 2025

BEIJING, Nov. 19, 2025 -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before U.S. markets open on Wednesday, December 3, 2025. Waterdrop's management team will hold a conference call on December 3, 2025 at 7:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for
- 황정호 기자
- 2025-11-19 18:00
KHB Highlights the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer at MEDICA 2025

XI'AN, China, Nov. 19, 2025 -- Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a global provider of in-vitro diagnostic (IVD) solutions, is showcasing its latest compact chemiluminescence platform—the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer—at MEDICA 2025, one of the world's leading medical industry exhibitions. As a featured product at this year's KHB booth, the Polaris V150 demonstrates the company's continuous innovation in automated diagnostics. Designed for small and medium-sized laboratories, as well as STAT and emergency testing in large hospitals a
- 김갑성 기자
- 2025-11-19 17:02
Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care

JERUSALEM, Nov. 19, 2025 -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract
- 김갑성 기자
- 2025-11-19 13:01
Older Singaporeans Support Healthier SG, but Lifestyle Habits Still Lag Behind

New SMU research reveals critical gaps in preventive health, lifestyle habits, and continuity of care as Singapore transitions into a super-aged society. Despite strong pro-health policies, everyday adoption - especially among older adults - remains limited. Bridging this gap requires environmental nudges that make healthy choices easier, more intuitive, and part of daily life. The upcoming symposium will explore these challenges and spotlight opportunities to strengthen pro-health behaviours. SINGAPORE, Nov. 19, 2025 -- A new study by the Singapore Management Uni
- 김갑성 기자
- 2025-11-19 12:30
Guo Guangchang: Fosun Joins Forces with Hong Kong to Advance Innovation and Globalization for Shared Success

HONG KONG, Nov. 19, 2025 -- On 18 November, the Chief Executive's Policy Unit (CEPU) of the Government of the Hong Kong Special Administrative Region, the National Academy of Economic Strategy of the Chinese Academy of Social Sciences, and the Chinese Institute of Hong Kong held the Economic Transformations in a Multipolar World - International Forum on China's Economy and Policy 2025 at the Central Government Offices. Guo Guangchang, Chairman of Fosun International, joined the session "The New Development Landscape of Hong Kong" and delivered a speech highlighting Hong Kong's pivot
- 황정호 기자
- 2025-11-19 10:32
밴티지 재단, 쿠알라룸푸르에서 케카라 무료 급식소 지원 나서

쿠알라룸푸르, 말레이시아 2025년 11월 19일 -- 밴티지 재단(Vantage Foundation)이 말레이시아의 대표적 비정부기구 케카라 수프 키친(Kechara Soup Kitchen, 줄여서 KSK)과 함께 지역 사회 돕기에 나섰다. KSK는 17년 넘게 도시 지역과 농촌 낙후 지역, 오랑 아슬리(Orang Asli), 무주택자 거주지에서 이웃을 돕고 있는 단체다. KSK는 '기아는 어디에나 있다'(Hunger Knows No Barriers)는 모토 아래 푸드뱅크, 교육 프로그램, 무료 급식소 등 여러 방법으로 이웃을 돕고 있다. 자원봉사 활동은 세타팍(Setapak) 소재 케카라 푸드뱅크에서 진행되었다. 필수 건조 식품과 생필품을 보관해 두었다가 도움이 필요한 가정에 나눠주는 곳이다. 밴티지 재단 직원 10명이 지원 프로그램에 참여하여 KSK 직원들과 함께 식량 원조 꾸러미를 만들어 전달했다. 직원들은 체라스(Cheras)와 진장(Jinjang)에서 궁핍하게 지내고 있는 것으로 확인된 여섯 가구를 방문했다. 소득이 낮거나 생활이 안정적이지 않은 가정, 장애인이 있는 가정, 독거 노인 가정 등이었다.&nb
- 황정호 기자
- 2025-11-19 10:26
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis (AD). This randomized, double-blind, vehicle-controlled Phase II study evaluated the efficacy and safety of topical LNK01004 ointment (0.3% and 1.0%) in adult patients with moderate-to-severe AD. A total of 75 patients were enroll
- 김갑성 기자
- 2025-11-19 08:00
Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care

JERUSALEM, Nov. 19, 2025 -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract
- 김갑성 기자
- 2025-11-19 06:00
라파 연구소, BARDA로부터 최대 1억 8600만 달러 지원받아… 병원 전 단계용 생명구조 근육주사형 TXA 개발 착수

예루살렘, 2025년 11월 19일 -- 라파 연구소(Rafa Laboratories)가 19일 미국 보건복지부(Department of Health and Human Services•HHS) 산하 전략적 대비•대응국(Administration for Strategic Preparedness and Response) 일원인 생물의학 첨단연구개발청(Biomedical Advanced Research and Development Authority•BARDA)으로부터 중대한 개발 계약을 수주했다고 발표했다. 이번 계약은 화학•생물•방사선•핵(CBRN) 위험 의료 대응 및 생물방어 분야의 글로벌 선도기업 라파가 BARDA와 체결한 두 번째 주요 계약으로, 모든 옵션 기간을 포함해 최대 1억 8600만 달러 규모다. 이와 같은 중대 협력은 전 세계가 직면한 긴급한 요구, 즉, 결정적인 병원 전 단계에서 신속하게 투여할 수 있으면서 사용이 용이한 출혈 치료에 대응할 수 있게 됐다는 점에서 중대한 의미를 가진다. 생명을 구하는 결정적 '골든타임' 내 대응 사고, 대량 사상자 발생 사건, 전장 중 어디서 발생하든 간에 통제되지 않은
- 김갑성 기자
- 2025-11-19 06:00

이전

81 82 83 84 85 86 87 88 89 90

많이 본 기사

최근기사

2026-03-03_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 12시 20분